Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02706-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Masatoshi Kanayama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Surgery, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pleural Neoplasms, Mesothelioma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitors (ICIs) have recently emerged as a promising strategy for the treatment of pleural mesothelioma (PM). METHODS: This retrospective study evaluated treatment efficacy and safety in Japanese patients with PM treated with nivolumab and ipilimumab (N + I group: 41 patients) as first-line therapy and nivolumab monotherapy (N group: 33 patients) as second- or later-line treatment. RESULTS: The median overall survival (OS) and progression-free survival (PFS) were not reached and 10.4 months in the N + I group, and 8.6 months and 3.5 months in the N group, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 68.3% of the N + I group and 72.7% of the N group, with grade 3-4 TRAEs in 19.5% and 12.1% of patients, respectively. Patients with an ECOG PS 0-1 had significantly better OS and PFS in both treatment groups (p < 0.001). In the N + I group, OS was significantly better in patients with TRAEs (p = 0.020) and in those with the epithelioid subtype (p = 0.047), although PFS was not significantly different (p = 0.138 and p = 0.154, respectively). In the N group, both OS (p = 0.007) and PFS (p = 0.048) were significantly longer in patients with TRAEs. CONCLUSION: This study provides valuable real-world clinical evidence of the efficacy and safety of nivolumab plus ipilimumab and nivolumab monotherapy in Japanese patients with PM. These results support the use of ICIs as a viable treatment option for advanced or relapsed disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Surgery, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. masatoshi-kanayama@med.uoeh-u.ac.jp.
- Second Department of Surgery, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
Förderung
- JSPS KAKENHI
Zitieren
APA
Kanayama, M., Manabe, T., Yoshimatsu, K., Oyama, R., Matsumiya, H., Mori, M., Takenaka, M., Kuroda, K., & Tanaka, F. (2025). Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02706-4
Vancouver
Kanayama M, Manabe T, Yoshimatsu K, Oyama R, Matsumiya H, Mori M, et al. Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02706-4
BibTeX
@article{Kanayama2025,
author = {Kanayama, Masatoshi and Manabe, Takehiko and Yoshimatsu, Katsuma and Oyama, Rintaro and Matsumiya, Hiroki and Mori, Masataka and Takenaka, Masaru and Kuroda, Koji and Tanaka, Fumihiro},
title = {Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02706-4}
}
EUVIMED